Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of 2-(allylthio) pyrazine, a chemoprotective agent, in rats: The role of CYP3A23 induction

Research Communications in Molecular Pathology and Pharmacology

Volumn 115-116, Issue , 2004, Pages 111-121

  Lee, Eun J ^a   Kim, Eun J ^a   Kim, Yoon G ^b   Chung, Hye C ^a   Kim, So H ^c   Kim, Dong H ^d   Lee, Inchul ^e   Kim, Sang G ^a   Lee, Myung G ^a  

^a Department of Pharmaceutics   (South Korea)

^b Dankook University   (South Korea)

^c Gangneung Wonju National University   (South Korea)

^d Korea Institute of Science and Technology   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

Author keywords

2 Allylthiopyrazine (AP); 3 methylcholanthrene; Acute renal failure; AP (2 allylthiopyrazine); CL (total body clearance); CYP1A1 2; CYP2B1 2; CYP3A1 2; Dexamethasone; Expression of cyp2e1; Expression of CYP3A(230; Inducers of CYP1A1 2; Pharmacokinetics of 2 AP

Indexed keywords

2 (ALLYLTHIO)PYRAZINE; 3 METHYLCHOLANTHRENE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DEXAMETHASONE; PHENOBARBITAL; PROTECTIVE AGENT; URANYL NITRATE; 2-(ALLYLTHIO)PYRAZINE; CYP3A23 PROTEIN, RAT; ORGANOMETALLIC COMPOUND; PYRAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE; URANYL ACETATE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; EXPERIMENTAL RAT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE; ANIMAL; AREA UNDER THE CURVE; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYME INDUCTION; KINETICS; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ENZYME INDUCTION; KIDNEY FAILURE, ACUTE; KINETICS; MALE; ORGANOMETALLIC COMPOUNDS; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34447251482     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bae, S.K., Lee, S.J., Kim, Y.H., Kim, J.W., Kim, S.G. and Lee, M.G. (2004). Effects of acute renal failure on the pharmacokinetics of oltipraz in rats. J. Pharm. Sci. (in press).
2. Bu, S.C., Kim, Y.G., Kim, S.H. and Lee, M.G. (2000). Effects of enzyme inducers and inhibitor on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agents, in rats. Biopharm. Drug Dispos. 21: 157-164.
3. Chiou, W.L. (1978). Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm. 6: 539-549.
4. Chiou, W.L. (1979). New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J. Pharm. Sci. 68: 1067-1069.
5. Chiou, W.L. (1980). New calculation method of mean total body clearance of drugs and its application to rationale regimens. J. Pharm. Sci. 69: 90-91.
6. Chung, H.C., Kim, S.H., Lee, M.G. and Kim, S.G (2002). Increase in urea in conjunction with L-arginine metabolism in the liver leads to induction of cytochrome P450 2E1 (CYP2E1): The role of urea in CYP2E1 induction by acute renal failure. Drug Metab. Dispos. 30: 739-746.
7. Correia, M.A. (1995). Appendix B. Rat and human liver cytochromes P450. Substrate and inhibitor specificities and functional markers. In: Oritz de Montellano, P.R. ed. Cytochrome P450. Structure, mechanism, and biochemistry. 2nd edn. Plenum Press, New York and London, pp. 607-630.
8. Eatman, F.B., Colburn, W.A., Boxenbaum, H.G., Posmanter, H.N., Weinfeld, R.E., Ronfeld, R., Weissman, L., Moore, J.D., Gibaldi, M. and Kaplan, S.A. (1977). Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J. Pharmacokinet. Biopharm. 5: 481-494.
9. Gibaldi, M. and Perrier, D. (1982). Pharmacokinetics, 2nd ed., Marcel Dekker, New York.
10. Han, K.S. and Lee, M.G. (1999). Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: Hepatic and gastric first-pass effects. Drug Metab. Dispos. 27: 221-226.
11. Han, K.S., Woo, S.-J., Koo, C.H. and Lee, M.G. (1998a). Determination of a chemoprotective agent, 2-(allylthio)pyrazine, in plasma, urine and tissue homogenates by high-performance liquid chromatography. J. Chromatogr. B. 710: 239-242.
12. Han, K.S., Woo, S.-J., Koo, C.H. and Lee, M.G. (1998b). Stability, blood partition, and protein binding of a chemoprotective agent, 2-(allylthio) pyrazine. Res. Commun. Mol. Pathol. Pharmacol. 101: 171-178.
13. Kim, S.H., Choi, Y.M. and Lee, M.G. (1993). Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J. Pharmacokinet. Biopharm. 21: 1-17.
14. X-174 DNA strand breakage. Yakhak Hoeji 40: 727-733.
15. Kim, N.D., Kwak, M.K. and Kim, S.G. (1997). Inhibition of cytochrome P4502E1 expression by 2-(allylthio)pyrazine, a potential chemoprotective agent: Hepatoprotective effects. Biochem. Pharmacol. 53: 261-269.
16. Kim, S.G., Nam, S.Y., Kim, C.W., Cho, C.K. and Kim, N.D. (1998). Radioprotective effects of 2-(allyllthio)pyrazine, an experimental chemopreventive agent: Effects on detoxifying enzyme induction. Res. Commun. Mol. Pathol. Pharmacol. 101: 275-288.
17. Moon, Y.J., Lee, A.K., Chung, H.C., Kim, E.J., Kim, S.H., Lee, D.C., Lee, I., Kim, S.G. and Lee, M.G. (2003). Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab. Dispos. 31: 776-784.
18. Surh, Y.-J., Park, K.K., Kim, S.G., Sohn, Y., Kim, N.D., Liem, A. and Miller, J.A. (1997). Chemoprevention of vinyl carbamate- or vinyl carbamate epoxide-induced hepatotoxicity, mutagenicity, and tumorigenicity by 2-(allylthio)pyrazine. Proc. Am. Assoc. Cancer Res. 38: 370.
19. Yu, S.Y., Chung, H.C., Kim, E.J., Kim, S.H., Lee, I., Kim, S.G. and Lee, M.G. (2002). Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: The role of CYP2E1 induction in 1,3-dimethyluric acid formation. J. Pharm. Pharmacol. 54: 1687-1692.